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INTRODUCTION
There has been an increasing trend in the use of contralateral 
prophylactic mastectomy (CPM) among women diagnosed with 
unilateral breast cancer (BC) or mutations in BRCA1 or BRCA2 
to reduce the occurrence of contralateral BC.
Therefore, it is desirable to understand the factors associated 
with the decision to undergo CPM in order to provide appro­
priate genetic counseling and risk­reduction strategies for high­
risk women. Previous studies indicated that women choosing 
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Purpose: There has been an increasing trend in the use of contralateral prophylactic mastectomy (CPM) among women 
diagnosed with unilateral breast cancer or mutations in BRCA1 or BRCA2 to reduce the occurrence of contralateral breast 
cancer. This study aimed to examine trends in the CPM rate according to clinicopathologic and socioeconomic status at a 
single institution in Korea.
Methods: This study included 128 patients with mutations in BRCA1 or BRCA2. Patients were divided into a CPM group (n = 8) 
and a non-CPM group (n = 120) between May 2013 and March 2016. The main outcome variables, including epidemiology, 
clinical features, socioeconomic status, and tumor characteristics, were analyzed.
Results: A total of 8 CPMs were performed among 128 patients. All CPM patients were married. The proportion of 
professional working women was higher in the CPM group (P = 0.049). Most patients who underwent CPM graduated 
college, compared to less than a third of the non-CPM group (P = 0.013). The CPM group had a higher rate of visits to the 
Hereditary Breast and Ovarian Cancer (HBOC) clinic (P = 0.021). The risk-reducing salpingo-oophorectomy (RRSO) rate 
was significantly higher in the CPM group (P < 0.01).
Conclusion: CPM rates were significantly different according to socioeconomic status. The CPM rate tends to increase 
in highly educated and professional working women. The socioeconomic status of patients is an important factor in the 
decision to participate in the HBOC clinic and undergo CPM or RRSO.
[Ann Surg Treat Res 2019;97(3):113-118]
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CPM are influenced more by their belief in the considerable risk 
of a new contralateral primary cancer than by medical evidence 
[1,2].
In 2013, Angelina Jolie announced that she is a carrier of 
the BRCA1 mutation and had undergone bilateral prophylactic 
mastectomy. This public attention was followed by a 2.5­fold 
increase in risk­reducing mastectomy rates in women with 
BRCA mutations, and has been described as “the Angelina Jolie 
effect” [3].
Women diagnosed with mutations in BRCA1 or BRCA2 have 
a high risk of developing BC. The average cumulative risk of 
BC in BRCA1 and BRCA2 mutation carriers was 65% and 45%, 
respectively [4]. Based on these results, a South Korean study 
found the cumulative risk of BC in BRCA1 and BRCA2 mutation 
carriers by age 70 years was 72.1% and 66.3%, respectively [5­7].
The advantages of CPM are a 95% reduction of risk for 
contralateral BC development in patients with BRCA mutations 
and a 90% reduction of risk in women with a strong family 
history [8,9].
Meanwhile, CPM has several disadvantages, including high 
cost, postoperative complications, and psychological distress 
[10]. The National Insurance System in the Republic of Korea 
did not cover the cost of CPM for patients with BRCA1 or BRCA2 
mutations until October 2017.
Most prior studies in Western countries suggested a 
relationship between socioeconomic status and trends in 
CPM rates [11­15]. However, these studies did not consider the 
relationship between CPM rates and clinicopathologic and 
socioeconomic status in Asian countries, including the Republic 
of Korea. To address limitations in the existing research, 
this study aimed to examine trends in CPM rates according 
to clinicopathologic and socioeconomic status at a single 
institution in the Republic of Korea.
METHODS
Patients
This study included 128 patients in the evaluation of 
CPM rates according to clinicopathologic and socioeconomic 
status. All participants in this study were enlisted at 
Severance Hospital between May 2013 and March 2016 and 
had been diagnosed with mutations in BRCA1 or BRCA2. 
Clinicopathologic features are described in Table 1. Written 
consent was obtained before blood sampling. The selection 
criteria for BRCA1 or BRCA2 screening were based on the 
Korean Hereditary Breast Cancer Study, which is covered by 
the National Insurance System (NIS). Surgery was performed 
in the CPM group (n = 8), but not in the non­CPM group (n 
= 120). The non­CPM group received chemoprevention or 
observation alone. Professional occupations included judicial 
officers, medical service personnel, or educators. Other workers 
performed clerical, blue­collar, or food preparation work, or 
worked as helpers or in sales.
Interpretation of genomic data
Sanger sequencing was performed by the Seoul Clinical 
Laboratories (http://www.scllab.co.kr/), which is certified by 
the College of American Pathologists laboratory accreditation 
program. References used for mutation identification with 
Sanger sequencing were the Breast Cancer Information Core 
database (http://research.nhgri.nih.gov/bic/) and the Human 
Genome Mutation Database (http://www.hgmd.org). Reporting 
of Sanger sequencing was performed using guidelines for 
mutation nomenclature of the Human Genome Variation 
Society (http://www.hgvs.org). Significant mutations were 
considered “positive” for BRCA1 or BRCA2, and variants of 
unknown significance and non­significant variants were 
considered “negative.”
Statistical analysis
A comparison of CPM rates was performed using the t­test. 
Socioeconomic and clinicopathologic status was compared using 
the chi­square/Fisher exact test and Mann­Whitney U­test in 
the 2 patient groups. Collected data underwent 2­tailed testing, 
and a P­value <0.05 was considered statistically significant. 
Collected data were analyzed using IBM SPSS Statistics ver. 24.0 
(IBM Co., Armonk, NY, USA).
Ethics
This study was approved by the Institutional Review Board of 
Severance Hospital (approval number: 2018­1802­001).
RESULTS
Among 8 patients who underwent CPM, 1 had partial 
mastectomy for a BC diagnosis in 2010, followed by bilateral 
total mastectomy 4 years later. Another 7 patients who 
underwent CPM for BC had modified radical mastectomy.
Among 128 patients in the study, the Hereditary Breast and 
Ovarian Cancer (HBOC) clinic provided treatment counseling 
for 55, and risk­reducing salpingo­oophorectomy (RRSO) was 
performed for 21.
Table 1 shows the clinicopathological features of 128 patients 
with mutations in BRCA1 or BRCA2. All patients in the CPM 
group had been diagnosed with BC, compared with 71.7% in the 
non­CPM group.
The median age at first diagnosis with BC in the non­CPM 
group was 41.6 years (range, 22.2–81.0 years), and was slightly 
higher than that in the CPM group, at 38.9 years (range, 30.8–
55.5 years). In the non­CPM group, the median age at diagnosis 
with contralateral BC was 48.9 years (range, 29.7–82.2 years), 
and the median age at diagnosis with ovarian cancer (OC) was 
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Table 1. Clinicopathological features of patients with BRCA1/2 mutations (n = 128)
Variable CPM (n = 8) Non-CPM (n = 120) P-value
Diagnosis of cancer 0.362 
    BC 8 (100) 86 (71.7)
    OC only 0 (0) 23 (19.2)
    Unaffected carrier 0 (0) 11 (9.1)
Age at first diagnosis with BC 38.9 (30.8–55.5) 41.6 (22.2–81.0) 0.542
Age at diagnosis with Contralateral BC - 48.9 (29.7–82.2)
Age at diagnosis with OC - 49.7 (28.8–78.7)
BRCA mutation 0.729
    BRCA1 4 (50) 68 (56.7)
    BRCA2 4 (50) 52 (43.3)
Family historya) 0.712
    Yes 4 (50.0) 73 (60.8)
    No 4 (50.0) 47 (39.2)
Marital status 0.533
    Divorced or widowed 0 (0) 4 (3.3)
    Married 8 (100) 95 (79.2)
    Single 0 (0) 20 (16.7)
    Unknown 0 (0) 1 (0.8)
Occupations 0.049
    Professional 2 (25.0) 5 (4.2)
    Other workers 4 (50.0) 39 (32.5)
    Homemaker 2 (25.0) 54 (45.0)
    Unknown 0 (0) 22 (18.3)
Education 0.013
    College graduate 7 (87.5) 39 (32.5)
    High school graduate or lower 1 (12.5) 59 (49.2)
    Unknown 0 (0) 22 (18.3)
Pathology of BC 0.291
    IDC 8 (100) 75 (62.5)
    ILC 0 (0) 1 (0.8)
    DCIS 0 (0) 4 (3.3)
    Unknown 0 (0) 6 (5.0)
    Non-BC 0 (0) 34 (28.3)
BC tumor size (T) 0.152
    T ≤ 1 3 (37.5) 43 (35.8)
    T ≥ 2 5 (62.5) 34 (28.3)
    Unknown 0 (0) 9 (7.5)
    Non-BC 0 (0) 34 (28.3)
BC lymph node (N) 0.002
    LN negative 1 (12.5) 50 (41.7)
    LN positive 7 (87.5) 27 (22.5)
    Unknown 0 (0) 9 (7.5)
    Non-BC 0 (0) 34 (28.3)
BC Stageb) 0.055
    Stage 0–1 1 (12.5) 34 (28.3)
    Stage 2–4 7 (87.5) 43 (35.8)
    Unknown 0 (0) 9 (7.5)
    Non-BC 0 (0) 34 (28.3)
Values are presented as number (%) or median (range).
CPM, contralateral prophylactic mastectomy; BC, breast cancer; OC, ovarian cancer; IDC, invasive ductal carcinoma; ILC, invasive 
lobular carcinoma; DCIS, ductal carcinoma in situ; LN, lymph node.  
a)BC or OC, within second degree. b)AJCC (American Joint Committee on Cancer) 7th edition.
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49.7 years (range, 28.8–78.7 years).
Half of the CPM group had a mutation in BRCA1, compared 
with 56.7% of the non­CPM group. A second­degree family 
history of BC was present in 73 patients in the non­CPM group 
(60.8%), compared with 4 patients in the CPM group (50%). All 
CPM group patients were married, compared with 95 in the 
non­CPM group (100% vs. 79% P = 0.533).
Half of the CPM group patients were nonprofessional (other) 
workers and a fourth were professional workers; however, 54 
of the non­CPM patients were homemakers (45%), 39 were 
nonprofessional (other) workers (32.5%), and only 5 were 
professional workers (4.2%). The proportion of professional 
working women was significantly higher in the CPM group 
(25.0% vs. 4.2%, P = 0.049).
All patients in the CPM group were college graduates, except 
for 1 who was a high school graduate. The educational level 
was significantly higher than in the non­CPM group, with only 
32.5% graduating college (P = 0.013).
The HBOC clinic provided treatment counseling for 55 
patients (43%). Fig. 1 shows clinical data for patients visiting the 
HBOC clinic. The median age was 38.5 years (range, 22.2–81.0 
years). Among the 55 patients, 41 (75.0%) had been diag­
nosed with BC and 8 were unaffected carriers of mutations in 
BRCA1/2. Fig. 2 compares the HBOC clinic attendance rates for 
the CPM and non­CPM groups. The CPM group had a higher 
rate of HBOC clinic attendance (87.5% vs. 40.0%, P = 0.021).
RRSO was performed in 21 patients (16.4%). Fig. 3 compares 
RRSO rates between the CPM and non­CPM group. Among 8 
patients in the CPM group, 6 (75%) underwent RRSO. RRSO was 
performed in 15 of 120 patients in the non­CPM group (12.5%). 
The RRSO rate was significantly higher in the CPM group (75.0% 
vs. 12.5%, P < 0.01).
DISCUSSION
This study showed that CPM rates were significantly different 
according to socioeconomic status. The CPM rate tended to 
increase in highly educated and professional working women. 
Socioeconomic status is an important factor in the decision to 
attend the HBOC clinic or undergo CPM and RRSO. The results 
are similar to those in previous studies in the United States 
showing that the CPM rate was associated with socioeconomic 
status, rather than tumor or biological characteristics [16,17].
In the current study, CPM rates were higher in professional 
workers than in other workers and homemakers (P = 0.049). 
The educational level in the CPM group was higher than 
in the non­CPM group (P = 0.013). As educational levels 
of professional workers are generally higher than those of 
Fig. 1. Clinical information on patients visiting the Hereditary 
Breast and Ovarian Cancer (HBOC) clinic with mutations in 
BRCA1/2 (n = 55). Fig. 2. Rates of attendance at the Hereditary Breast and 
Ovarian (HBOC) clinic in contralateral prophylactic mastec-
tomy (CPM) group and non-CPM group patients with mu-
tations in BRCA1/2 (n = 128).
Fig. 3. Risk-reducing salpingo-oophorectomy (RRSO) rates in 
contralateral prophylactic mastectomy (CPM) and non-CPM 
group patients with mutations in BRCA1/2 (n = 128).
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nonprofessional workers, the findings confirmed that this was 
a significant factor in the decision to undergo CPM.
In addition, the study showed that the attendance rate in 
the HBOC clinic and the RRSO rate in the CPM group were 
significantly higher than in the non­CPM group (P = 0.021, P 
< 0.01). This result also reflected the higher educational level 
in the CPM group. This may imply that women with a higher 
educational level have access to better health care information 
and are more likely to understand this information.
Socioeconomic status was determined using 3 criteria: 
income, education, and occupation. Higher levels of education 
are associated with better economic and psychological 
outcomes. The occupational status reflects the educational 
attainment required to obtain a better job and income level 
[18,19]. Thus, the current study verified that socioeconomic 
status is an important factor in the decision to attend the HBOC 
clinic or undergo CPM and RRSO.
The trends in CPM rates according to clinicopathologic and 
socioeconomic status should be considered in clinical practice, 
because providing adequate information and appropriate 
education according to socioeconomic status is important 
for women with BRCA1/2 mutations who are considering 
risk­reduction procedures. It is necessary to provide more 
detailed information and to construct a care system for breast 
reconstruction.
The efficacy of CPM has been controversial since its 
inception. Many studies showed that CPM significantly reduces 
the risk for contralateral BC among BRCA1/2 mutation carriers, 
but without improvement of overall survival in a follow­up 
period [20­22]. And, although mastectomy is generally safe and 
associated with high satisfaction rate, women still experience 
long­term effects as cosmetic, psychological, and social domains 
[22,23]. Further studies for a survival benefit and long­term side 
effects from CPM are necessary to provide the information to 
women with BRCA1/2 mutations so that they can make the 
right choice for risk­reducing strategies.
Our study has limitations. This was a retrospective study 
with a small sample size in single institution. Enrolled patients 
were heterogeneous including unaffected carrier. The collected 
data regarding socioeconomic factors did not represent income 
levels and careers, which may have contributed to the lack of 
significant results. However, this is the first study on trends in 
CPM in the Republic of Korea.
Fortunately, the NIS began to cover the cost of CPM for 
patients with BRCA1 or BRCA2 mutations in October 2017 [24]. 
Further study to evaluate the impact of support by the NIS for 
CPM is necessary
In conclusion, the rate of CPM tends to increase in highly 
educated and professional working women. Socioeconomic 
status is an important factor in the decision to attend the 
HBOC clinic or undergo CPM and RRSO. Clinicians should 
take socioeconomic differences into account to provide 
individualized risk­reducing strategies for women with BRCA1/2 
mutations.
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